435 related articles for article (PubMed ID: 32799584)
1. Novel therapeutic agents for the treatment of diabetic kidney disease.
Hartman RE; Rao PSS; Churchwell MD; Lewis SJ
Expert Opin Investig Drugs; 2020 Nov; 29(11):1277-1293. PubMed ID: 32799584
[TBL] [Abstract][Full Text] [Related]
2. New progress in drugs treatment of diabetic kidney disease.
Wang J; Xiang H; Lu Y; Wu T; Ji G
Biomed Pharmacother; 2021 Sep; 141():111918. PubMed ID: 34328095
[TBL] [Abstract][Full Text] [Related]
3. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
Bell DSH; Jerkins T
Diabetes Obes Metab; 2024 Jun; 26(6):2046-2053. PubMed ID: 38516874
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the pharmacotherapeutic management of diabetic kidney disease.
Block TJ; Batu D; Cooper ME
Expert Opin Pharmacother; 2022 May; 23(7):791-803. PubMed ID: 35522659
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
Zou H; Zhou B; Xu G
Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
[TBL] [Abstract][Full Text] [Related]
6. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
Gohda T; Murakoshi M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
Barrera-Chimal J; Jaisser F
Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
[TBL] [Abstract][Full Text] [Related]
9. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.
Kim DL; Lee SE; Kim NH
Endocrinol Metab (Seoul); 2023 Feb; 38(1):43-55. PubMed ID: 36891650
[TBL] [Abstract][Full Text] [Related]
10. New Glucose-Lowering Agents for Diabetic Kidney Disease.
de Vos LC; Hettige TS; Cooper ME
Adv Chronic Kidney Dis; 2018 Mar; 25(2):149-157. PubMed ID: 29580579
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y; Godoy LC; Scholtes RA; van Raalte DH; Cherney DZ
Curr Diab Rep; 2019 Jan; 19(1):4. PubMed ID: 30673886
[TBL] [Abstract][Full Text] [Related]
12. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
Warren AM; Knudsen ST; Cooper ME
Expert Opin Ther Targets; 2019 Jul; 23(7):579-591. PubMed ID: 31154867
[No Abstract] [Full Text] [Related]
13. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists.
Winiarska A; Knysak M; Nabrdalik K; Gumprecht J; StompĆ³r T
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639160
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects.
Garofalo C; Borrelli S; Liberti ME; Andreucci M; Conte G; Minutolo R; Provenzano M; De Nicola L
Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212638
[TBL] [Abstract][Full Text] [Related]
15. Advancements in diabetic kidney disease management: integrating innovative therapies and targeted drug development.
Ghose S; Satariano M; Korada S; Cahill T; Shah R; Raina R
Am J Physiol Endocrinol Metab; 2024 Jun; 326(6):E791-E806. PubMed ID: 38630049
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
17. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches.
Mima A
Adv Ther; 2022 Aug; 39(8):3488-3500. PubMed ID: 35751762
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions.
Tommerdahl KL; Kula AJ; Bjornstad P
Expert Opin Pharmacother; 2023 Jun; 24(8):913-924. PubMed ID: 37071054
[TBL] [Abstract][Full Text] [Related]
20. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]